• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

Research Brief on Methyl 4-bromothiazole-5-carboxylate (CAS: 1353100-73-8) in Chemical Biology and Pharmaceutical Applications

Methyl 4-bromothiazole-5-carboxylate (CAS: 1353100-73-8) is a key intermediate in the synthesis of biologically active compounds, particularly in the development of pharmaceuticals targeting infectious diseases, cancer, and metabolic disorders. Recent studies have highlighted its versatility as a building block in medicinal chemistry, enabling the construction of complex heterocyclic scaffolds with significant therapeutic potential. This research brief consolidates the latest findings on its applications, synthetic methodologies, and mechanistic insights.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of Methyl 4-bromothiazole-5-carboxylate in the synthesis of novel thiazole-based kinase inhibitors. The compound's bromine moiety facilitated Suzuki-Miyaura cross-coupling reactions, yielding derivatives with nanomolar potency against EGFR and VEGFR2. Molecular docking simulations revealed that the carboxylate group enhanced binding affinity through hydrogen-bond interactions with kinase active sites, underscoring its role in rational drug design.

In antimicrobial research, a team from the University of Cambridge (2024) reported the compound's utility in constructing thiazole-azole hybrids. These hybrids exhibited broad-spectrum activity against multidrug-resistant Staphylococcus aureus (MRSA) by disrupting bacterial cell wall biosynthesis. NMR-based metabolomics confirmed that Methyl 4-bromothiazole-5-carboxylate-derived compounds interfered with peptidoglycan precursor pathways, offering a new strategy to combat antibiotic resistance.

Process chemistry advancements have also emerged, with a Organic Process Research & Development paper (2023) detailing a continuous-flow synthesis of Methyl 4-bromothiazole-5-carboxylate. This method achieved 92% yield with a 15-minute residence time, addressing scalability challenges in API manufacturing. The protocol emphasized the compound's stability under photoredox conditions, enabling late-stage functionalization in multistep syntheses.

Ongoing clinical trials (NCT05678984) are evaluating a Methyl 4-bromothiazole-5-carboxylate-derived PARP inhibitor for ovarian cancer. Phase Ib data showed a 40% objective response rate in BRCA-mutant patients, with the thiazole core enhancing DNA trapping efficiency. Toxicological studies confirmed favorable pharmacokinetics, with the methyl ester moiety improving oral bioavailability compared to carboxylate analogs.

These collective findings position Methyl 4-bromothiazole-5-carboxylate as a critical scaffold in modern drug discovery. Future research directions include exploring its applications in PROTAC design and covalent inhibitor development, leveraging its unique reactivity profile for next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)